NIM
NBIX icon

NEOS Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

NEOS Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,548
Closed -$503K – 628
2025
Q4 		$503K Sell
3,548
-110
-3% -$15.9K ﹤0.01% 605
2025
Q3 		$514K Sell
3,658
-246
-6% -$33.3K ﹤0.01% 577
2025
Q2 		$491K Hold
3,904
– – 0.01% 548
2025
Q1 		$432K Buy
3,904
+58
+2% +$7.35K 0.01% 528
2024
Q4 		$525K Hold
3,846
– – 0.01% 497
2024
Q3 		$443K Buy
3,846
+294
+8% +$40.3K 0.01% 507
2024
Q2 		$489K Hold
3,552
– – 0.02% 457
2024
Q1 		$490K Buy
+3,552
New +$485K 0.03% 389

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NEOS Investment Management's NBIX Position: Q1 2026 in Review

NEOS Investment Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 3,548 shares — an estimated $503K sold.

NEOS Investment Management first reported a position in NBIX in Q1 2024 and held it in 8 quarters. The position peaked at $525K in Q4 2024. 699 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • NEOS Investment Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • NEOS Investment Management sold 3,548 Neurocrine Biosciences shares in Q1 2026, an estimated $503K.
  • NEOS Investment Management first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 8 quarters.
  • NEOS Investment Management's Neurocrine Biosciences position peaked at $525K in Q4 2024.
  • 699 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on NEOS Investment Management's 13F filing for Q1 2026, filed 15 May 2026.